1964. Deputy John Connolly asked the Minister for Health the specific actions being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreich’s ataxia in the ongoing price negotiations for Skyclarys (Omaveloxolone); the way in which the commitments contained within the National Rare Disease Strategy 2025–2030 and the 2026 IPHA Framework Agreement, including the 180-day decision timeline, are being applied in this case to avoid further delays in access to treatment for patients (details supplied); and if she will make a statement on the matter. [19731/26]

Summary

1964. Deputy John Connolly asked the Minister for Health the specific actions being taken to ensure that the HSE recognises and responds to the time-critical nature of Friedreich’s ataxia in the ongoing price negotiations for Skyclarys (Omaveloxolone); the way in which the commitments contained within the National Rare Disease Strategy 2025–2030 and the 2026 IPHA Framework Agreement, including the 180-day decision timeline, are being applied in this case to avoid further delays in access to treatment for patients (details supplied); and if she will make a statement on the matter. [19731/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 18 March 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.